Clinical Trial Update: Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers [Phase 1]

View source ↗

Summary

Phase 1 ADME study evaluating single-dose [14C] Selumetinib in volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumours

Drugs mentioned

• Selumetinib (Koselugo) (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Solid Tumours | Phase 1 | Status: COMPLETED